Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (74)

« Back to Publications

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.

Luo J. et al, (2024), Mucosal immunology, 17, 524 - 536

Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19

Luo J. et al, (2024)

Neuromedin U promotes human type 2 immune responses.

Ye Y. et al, (2022), Mucosal immunology, 15, 990 - 999

Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19

Luo J. et al, (2021), Allergy, Asthma & Clinical Immunology, 17

The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism

Chen W. et al, (2021), The Journal of Immunology, 206, 2714 - 2724

Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells.

Luo J. et al, (2019), The Journal of allergy and clinical immunology, 144, 1722 - 1726.e10

Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.

Hardman C. et al, (2019), The Journal of allergy and clinical immunology, 143, 2329 - 2333

Correction: Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma

Hilvering B. et al, (2019), Mucosal Immunology, 12, 581 - 581

Fevipiprant, a Selective Prostaglandin D2Receptor 2 Antagonist, Potently Inhibits Chemotaxis and Cytokine Production by Tc2 cells (type-2 CD8+lymphocytes)

Xue L. et al, (2019), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 199

FEVIPIPRANT INHIBITS PROSTAGLANDIN D2 MEDIATED ACTIVATION OF GROUP 2 INNATE LYMPHOID CELLS (ILC2S)

Sandham D. et al, (2019), RESPIROLOGY, 24, 105 - 105

Type-2 CD8+ T lymphocytes responsive to PGD2/LTE4 in severe eosinophilic asthma

Hinks T. et al, (2018), Airway Cell Biology and Immunopathology, OA4927 - OA4927

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma

Hilvering B. et al, (2018), Mucosal Immunology, 11, 1408 - 1419

Effects of Steroids in Cultured Human Type-2 Cytokine Producing Cells

Luo J. et al, (2018), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197

Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Potently Inhibits Chemotaxis and Cytokine Production by Group 2 Innate Lymphoid Cells

Xue L. et al, (2018), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197

Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)

Chen W. et al, (2018), EUROPEAN RESPIRATORY JOURNAL, 52

Load More

1
2
3
4
5